Co-Authors
This is a "connection" page, showing publications co-authored by MAKSIM MAMONKIN and RAYNE ROUCE.
Connection Strength
0.733
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241.
Score: 0.249
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.155
-
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
Score: 0.135
-
Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023 03; 29(3):165.e1-165.e7.
Score: 0.057
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.055
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.043
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.039